logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
August 19, 2024
by info@virtueinsight.comNews

Mankind Pharma acquires Bharat Serums and Vaccines for $1.6bn

  Mankind Pharma has announced a definitive agreement for the acquisition of a 100% stake in Bharat Serums and Vaccines (BSV) from private equity investor Advent International in a Rs136.3bn ($1.6bn) deal. The move bolsters Mankind Pharma’s position in the Indian women’s...
read more
August 19, 2024
by info@virtueinsight.comNews

Eli Lilly inaugurates R&D facility in Boston

Eli Lilly and Company has opened the Lilly Seaport Innovation Center (LSC), a research and development (R&D) hub in the Seaport district of Boston, US. The centre is set to progress the company’s work on RNA and DNA-based therapies and discover new drug targets for...
read more
August 19, 2024
by info@virtueinsight.comNews

Boehringer Ingelheim acquires Nerio Therapeutics for $1.3bn

  Boehringer Ingelheim has acquired drug discovery and development company Nerio Therapeutics in a $1.3bn deal. Nerio’s small molecules inhibit the protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which act as immune checkpoints. Through this mechanism, PTPN1/2...
read more
August 19, 2024
by info@virtueinsight.comNews

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Biogen has completed the acquisition of Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). “We are very excited about the addition of felzartamab into our...
read more
July 4, 2024
by info@virtueinsight.comNews

AbbVie completes acquisition of Celsius Therapeutics for $250m

US-based biopharmaceutical company AbbVie has acquired Celsius Therapeutics, a biotechnology company developing therapies for inflammatory diseases, for $250m. The strategic move expands AbbVie’s footprint in the treatment of inflammatory diseases, adding a potentially transformative...
read more
July 4, 2024
by info@virtueinsight.comNews

Sanofi and Belharra forge $700m partnership for immunological diseases

  Belharra Therapeutics has announced that it has entered a strategic partnership with global powerhouse Sanofi to spur the development of small molecule therapies for immunological diseases. Under the terms of the agreement, the San Diego, California-based next-generation...
read more
July 4, 2024
by info@virtueinsight.comNews

ANI Pharmaceuticals to Acquire Alimera Sciences

  ANI Pharmaceuticals and Alimera Sciences had announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per...
read more
July 4, 2024
by info@virtueinsight.comNews

EQT Acquires Majority Stake in CluePoints

EQT is pleased to announce that the EQT Healthcare Growth Strategy and the EQT Growth Fund have agreed to acquire a majority stake in CluePoints  with meaningful reinvestment from the management team and existing shareholders Summit Partners and Clinimetrics SA, which was also a...
read more
May 13, 2024
by info@virtueinsight.comNews

AstraZeneca Withdraws Covid-19 Vaccine Worldwide

Anglo-Swedish drugmaker AstraZeneca  on Wednesday announced the global withdrawal of its Covid-19 vaccine Vaxzevria. Demand for AstraZeneca’s Vaxzevria vaccine began tapering off as new vaccines tailored to specific Covid variants have emerged, the pharmaceutical company said in a...
read more
May 13, 2024
by info@virtueinsight.comNews

AbbVie to buy Landos Biopharma for up to $212M

  AbbVie Inc. and Landos Biopharma, Inc.  had announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead...
read more
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
logotype

We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.

Facebook-fTwitterYoutubeLinkedin-inInstagramPinterest

Quick Links

About us
Contact us
Event Support
Careers
Privacy Policy
Terms & Conditions

Subscribe to our newsletter

    © 2025 Virtue Insight. All rights reserved.